Ever since the coronavirus hit the residents of Wuhan, the capital city of Hubei Province in China, it has been the subject of research in all of the world’s premier medical research institutions. As there was a lot of cloudiness, on the origin of this virus and its transmission from animals to human beings, it became increasingly difficult to perform studies on this virus.
There is no specific antiviral treatment for the virus as of now, but patients are being isolated and quarantined to contain the spread of the virus. Because the time for the manifestation of this virus in a human body is very little, researchers find it difficult to work on patient bodies and work on improving and testing medicines. The clue to a medicine being worked out for the virus depends on how this virus has started infecting human beings after being dormant in the body of its previous host.
As more information is getting poured in for making a cure and hospitals are working to stabilize the current patients by supporting their lungs and other vital organs, a lot of the onus is on the testing techniques that are being utilized to isolate the infected patients from those that are not infected. The Center for Disease Control and Prevention (CDC) in the United States has worked out a testing kit called “Centers for Disease Control and Prevention (CDC) 2019-Novel Coronavirus (2019-nCoV) Real-Time Reverse Transcriptase (RT) -PCR Diagnostic Panel”.
This test kit is used on patients that meet the criteria of the testing set by the CDC and have been observed with coronavirus symptoms. It takes the upper and lower respiratory specimens for analyzing. These test kits are shipped to laboratories (identified and certified by the CDC) around the globe to expedite the testing process and enhance the efficiency, reliability and robustness of the testing procedure.
